Haisco Pharmaceutical Group Co., Ltd

Haisco Pharmaceutical Group is a leading fully integrated pharmaceutical company headquartered in China, publicly traded on the Shenzhen Stock Exchange (SZEX: 002653) with a market capitalization of approximately $6 billion. Innovation-Driven R&D With a dedicated in-house R&D team of 800+ scientists and three proprietary technology platforms—Targeted Protein Degradation, Small Molecule Drug Discovery, and Inhalation Delivery Systems—Haisco has built a robust pipeline of 20+ novel chemical entities (NCEs). These programs target high-need therapeutic areas, including: Central Nervous System (CNS), Oncology, Respiratory Diseases, Immunology, Metabolic Disorders Strategic Collaborations & Licensing Success Haisco’s innovation has attracted global partnerships, including: Out-licensing of a TYK2 inhibitor to Alumis (Nasdaq: ALMS), which subsequently secured $210 million in funding and achieved a successful Nasdaq IPO. Exclusive worldwide rights (ex-China) for a DPP1 inhibitor in respiratory diseases granted to Chiesi Group, underscoring Haisco’s leadership in respiratory therapeutics. Leveraging its scientific expertise and scalable infrastructure, Haisco remains committed to advancing transformative therapies while fostering strategic alliances to accelerate global patient access.